Knight Therapeutics Q3 EPS $(0.03) Misses $0.01 Estimate, Sales $137.691M Beat $129.202M Estimate

Benzinga · 1d ago
Knight Therapeutics (TSX:GUD) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.01 by 400 percent. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $137.691 million which beat the analyst consensus estimate of $129.202 million by 6.57 percent. This is a 13.28 percent increase over sales of $121.548 million the same period last year.